First UK Fixed Revenue-Per-Procedure Service Available at Capio Springfield Hospital

EDAP Ablatherm-HIFU Strongly Highlighted in European Congresses LYON, France , June 18 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports continued and sustained marketing presence in various

EDAP to Add University of Colorado Under Direction of Dr. David Crawford to Clinical Study LYON, France , June 5 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, intends to add the University of

EDAP Looking to Accelerate US Study Enrollment With the Upcoming Addition of McMaster University Hospital LYON, France , June 1 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports further

EDAP Ablatherm-HIFU Presents at American Urology Association Accelerates US Study Enrollment LYON, France , May 23 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports the continuing advancement

Long-Term European Results Highlight the Importance of This Study for U.S.

European Marketing and Education Strategy Validated

European RPP Program on Target for 2008 Profitability; FDA Trial Launch Positions EDAP for Direct USA Control; EDAP, China Medical Alliance Unites HIFU Leaders

EDAP to Accelerate Treatment Rates at Study Centers

EDAP TMS S.A. to Release 2007 First Quarter Results LYON, France , May 7 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution